Results 11 to 20 of about 21,171,014 (388)
In Silico Assessment of Limited Blood Sampling Strategies for Individualised Pharmacokinetic‐guided Dosing of Efanesoctocog Alfa in Haemophilia A Patients [PDF]
Haemophilia, EarlyView.ABSTRACT Introduction Efanesoctocog alfa is a novel factor VIII (FVIII) concentrate with a unique molecular design that enables Von Willebrand Factor‐independent clearance in patients with haemophilia A. Limited sampling strategies (LSSs) are necessary to implement accurate pharmacokinetic (PK)‐guided dosing for efanesoctocog alfa in clinical practice.
Jan den Hollander +2 more
openalex +2 more sources
The B-team: Equal but different?
The Journal of Haemophilia Practice, 2021 As a person with haemophilia B, I have known there are differences between haemophilia A and haemophilia B and their respective treatment throughout my life – though I was shocked when I learnt about the impact inhibitors can have when it comes to ...
Pembroke Luke
doaj +1 more source
Haemophilia specialist nurses’ perceptions of haemophilia B
The Journal of Haemophilia Practice, 2021 Some clinicians believe that haemophilia B is associated with less bleeding than haemophilia A, yet there appears to be little difference in health-related outcomes.
Chaplin Steve +9 more
doaj +1 more source
Haemophilia, 2021 Few studies have examined the real‐world impact of haemophilia on daily activities and work productivity in people with severe haemophilia A (PWSHA).
J. O’Hara +7 more
semanticscholar +1 more source
European Journal of Case Reports in Internal Medicine, 2022 Introduction: Severe haemophilia A is characterized by serious factor VIII deficiency (biological activity
Dorina Cultrera, Sergio Cabibbo
doaj +1 more source
Adherence to prophylaxis in adolescents and young adults with severe haemophilia: a qualitative study with healthcare professionals [PDF]
, 2020 © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits ...
Hart, Daniel +3 more
core +3 more sources
Living, Caring, Learning – Early education, active lives and tailored treatment in haemophilia care
The Journal of Haemophilia Practice, 2023 Josipa, a haemophilia nurse in Croatia, describes how meeting 18-year-old twins with severe haemophilia A changed her views around joint health and activity in people with haemophilia.
Belev Josipa
doaj +1 more source
Adeno‐associated virus serotype 2 capsid variants for improved liver‐directed gene therapy
Hepatology, EarlyView., 2022 Abstract Background and Aims Current liver‐directed gene therapies look for adeno‐associated virus (AAV) vectors with improved efficacy. With this background, capsid engineering is explored. Whereas shuffled capsid library screenings have resulted in potent liver targeting variants with one first vector in human clinical trials, modifying natural ...
Nadja Meumann +25 more
wiley +1 more source
The Journal of Haemophilia Practice, 2022 In children with haemophilia (CwH), central venous access devices (CVADs) are frequently placed to aid in the delivery of factor concentrates. In those who develop inhibitors, CVADs also allow for easy venous access and facilitation of immune tolerance ...
Kwan Celia +6 more
doaj +1 more source
Living, Caring, Learning – Trust and teamwork in patient care
The Journal of Haemophilia Practice, 2023 Marcela, a nurse specialist in Brazil, reflects on the importance of trust in the therapeutic relationship in achieving the best patient outcomes. She describes her experience with a patient with severe haemophilia A and an inhibitor. The patient was non-
Sisdelli Marcela Ganzella
doaj +1 more source